Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Authors:
- Tania MullerTMTania Muller
- Laurent DemizieuxLDLaurent Demizieux
- Stéphanie Troy-FioramontiSTStéphanie Troy-Fioramonti
- Chloé BuchCBChloé Buch
- Julia LeemputJLJulia Leemput
- Christine BelloirCBChristine Belloir
- Jean-Paul Pais de BarrosJBJean-Paul Pais de Barros
- Tony JourdanTJTony Jourdan
- Patricia Passilly-DegracePPPatricia Passilly-Degrace
- Xavier FioramontiXFXavier Fioramonti
- Anne-Marie Le BonABAnne-Marie Le Bon
- Bruno VergèsBVBruno Vergès
Open Access
- 8 March 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2923
Abstract
Targeting cannabinoid 1 receptors (CB1R) with peripherally restricted antagonists (or inverse agonists) shows promise to improve metabolic disorders associated with obesity. In this context, we designed and synthetized JM-00266, a new CB1R blocker with limited blood–brain barrier (BBB) permeability. Pharmacokinetics were tested with SwissADME and in vivo in rodents after oral and intraperitoneal administration of JM-00266 in comparison with Rimonabant. In silico predictions indicated JM-00266 is a non-brain penetrant compound and this was confirmed by brain/plasma ratios and brain uptake index values. JM-00266 had no impact on food intake, anxiety-related behavior and body temperature suggesting an absence of central activity. cAMP assays performed in CB1R-transfected HEK293T/17 cells showed that the drug exhibited inverse agonist activity on CB1R. In addition, JM-00266 counteracted anandamide-induced gastroparesis indicating substantial peripheral activity. Acute administration of JM-00266 also improved glucose tolerance and insulin sensitivity in wild-type mice, but not in CB1R−/− mice. Furthermore, the accumulation of JM-00266 in adipose tissue was associated with an increase in lipolysis. In conclusion, JM-00266 or derivatives can be predicted as a new candidate for modulating peripheral endocannabinoid activity and improving obesity-related metabolic disorders.Keywords
Funding Information
- Société Francophone du Diabète (paf/cc 14-005)
- Agence Nationale de la Recherche (ANR-11-LABX-0021)
This publication has 61 references indexed in Scilit:
- Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in MiceGastroenterology, 2012
- The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptorsThe Journal of Physiology, 2011
- Thermoregulatory Phenotype of theTrpv1Knockout Mouse: Thermoeffector Dysbalance with HyperkinesisJournal of Neuroscience, 2011
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesityJournal of Clinical Investigation, 2010
- CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese MiceDiabetes, 2010
- Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese RatsDiabetes, 2008
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJournal of Clinical Investigation, 2008
- [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptorProceedings of the National Academy of Sciences, 2007
- Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal ObesityDiabetes, 2006
- Investigation on the relationship between cannabinoid CB1and opioid receptors in gastrointestinal motility in miceBritish Journal of Pharmacology, 2006